Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, calls to local poison control centers about side effects, incorrect dosing and other types of exposure are on a steep rise
Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with alcohol use disorder (AUD) and either type 2 diabetes or obesity who started a newer GLP-1 RA (semaglutide, tirzepatide) to similar individuals starting alternative medications
Clinical studies have shown that the most significant results are often observed after 12 months of consistent use, with ongoing benefits as long as therapy continues
Here we break down the main pros and cons based on available information, customer reports, and typical probiotic considerations
This research necessitates continued exploration, potentially revolutionizing future therapeutic strategies
Jendle J, Grunberger G, Blevins T, et al